Abstract 13360: Impact of Aortic Valve Calcification on the Incidence of Periprocedual Myocardial Injury in Patients Undergoing Coronary Stent Implantation
Object: Previous studies have shown an association between aortic valve calcification (AVC) and cardiovascular events and mortality. On the other hand, periprocedual myocardial injury (PMI) is known as a predictor of subsequent mortality and other poor clinical outcomes.
Hypohtesis: We assessed the hypothesis that presence of AVC could predict PMI in elective percutaneous coronary intervention (PCI).
Methods: This study included a total of 372 patients treated with PCI for stable angina pectoris. Aortic valve calcification was defined as bright echoes >1mm on one or more cusps of aortic valve by ultrasound cardiography. PMI was defined as an increase in high-sensitivity troponin T >5 times (0.070 ng/ml) the upper normal limit at 24hours after PCI.
Results: AVC was detected in 46.0% (n = 171). The incidence of PMI was significantly higher in patients with AVC than in those without AVC (43.9% vs 10.9%, respectively, p < 0.001). The presence of AVC independently predicted PMI after adjusting for other significant variables (OR 2.18, 95% CI 1.30 to 3.66, p = 0.003). Other predictors were estimated glomerular filtration rate (OR 0.975, 95% CI 0.962 to 0.989, p < 0.001), left anterior descending artery lesion (OR 0.496, 95% CI 0.293 to 0.840, p = 0.01) and total stent length (odds ratio 1.02, 95% confidence interval 1.00 to 1.05, p = 0.03).
Conclusion: In conclusion, presence of AVC could predict incidence of PMI. Because detection of AVC by ultrasound cardiography is very simple, it is useful for risk stratifications in elective PCI with stent implantation.
Author Disclosures: Y. Shibata: None. S. Suzuki: None. H. Ishii: Honoraria; Significant; Astellas, Otsuka. K. Harada: None. K. Hirayama: None. Y. Tatami: None. T. Ota: None. T. Murohara: Research Grant; Significant; Astellas, Daiichi Sankyo, Daiichi Sankyo, Kowa, MSD, Mitsubishi Tanabe, Nippon Boehringer Ingelheim, Otsuka, Pfizer Japan, Sanofi- Aventis, Takeda, Teijin. Honoraria; Modest; Bayer, Daiichi Sankyo, Dainippon Sumitomo, Kowa, MSD, Mitsubishi Tanabe, Nippon Boehringer Ingelheim, Pfizer Japan, Sanofi- Aventis, Takeda.
- © 2015 by American Heart Association, Inc.